GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Natera Inc.
Natera is a pioneer in genetic testing based on free DNA analysis. Its tests are used in reproductive medicine and oncology. The volatile stock price reflects both the enormous potential of this technology and the risks associated with medical research.
Share prices of companies in the market segment - Reproduction
Natera is a leader in genetic testing, serving the reproductive health (non-invasive prenatal tests) and oncology sectors. We classify it as part of the Reproduction sector. The chart below shows the overall dynamics of this rapidly growing market.
Broad Market Index - GURU.Markets
Natera is a leader in genetic testing, providing tests for reproductive health, oncology, and transplantation. Its innovations have earned it a spot in the GURU.Markets index. The chart below represents the market. See if Natera is outperforming the overall biotech sector.
Change in the price of a company, segment, and market as a whole per day
NTRA - Daily change in the company's share price Natera Inc.
Natera is a leader in genetic testing, from prenatal diagnostics to cancer monitoring. Its daily share price reflects its high volatility and sensitivity to news in the biotech sector. This metric is a key component in the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Reproduction
Natera, Inc. is a leader in genetic testing. This chart reflects the highly volatile biotech sector. Comparison with NTRA's performance, which depends on the adoption of its tests in reproductive medicine and oncology, helps assess its growth and risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Natera is a leader in genetic testing, specializing in reproductive health and oncology. This sector is one of the most advanced and volatile in biotech. The chart below reflects the extreme fluctuations typical of this industry, where news can dramatically change a company's valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Natera Inc.
Загрузка...
Annual dynamics of market capitalization of the market segment - Reproduction
Natera, Inc. is a leader in genetic testing, specializing in reproductive health and oncology. Its innovative tests are changing approaches to diagnostics. This chart shows how the market perceives the potential of its technology and its rapid growth compared to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Natera is a company specializing in genetic testing, particularly in reproductive health and oncology. Its growth is driven by the expanding use of its tests. Natera's stock performance is a story of medical innovation unrelated to the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Natera Inc.
Natera, a genetic testing company, is highly dependent on operational news for its value. Monthly fluctuations on the chart reflect the volume of tests performed, insurance company reimbursement decisions, and, most importantly, clinical trial data confirming the accuracy of its tests.
Monthly dynamics of market capitalization of the market segment - Reproduction
Natera, Inc. is a pioneer in non-invasive genetic testing, ranging from reproductive health to cancer diagnostics. The biotech sector, whose performance is shown on the chart, is extremely sensitive to scientific breakthroughs and regulatory decisions. This allows us to assess how Natera's innovations have been received by the market against the backdrop of overall investor sentiment in this complex industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Natera is a leader in non-invasive prenatal testing and DNA-based cancer diagnostics. It is a fast-growing company in the healthcare sector. The overall market performance chart shows how strong its own growth trend, driven by the introduction of its tests, allows Natera's shares to move independently of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Natera Inc.
Natera, a company specializing in genetic testing, particularly in reproductive medicine, exhibits high volatility. Weekly stock price fluctuations reflect news about the introduction of new tests, insurance company coverage decisions, and clinical trial data, revealing the pulse of innovation in genetics.
Weekly dynamics of market capitalization of the market segment - Reproduction
Natera, a genetic testing company, often moves in line with the broader biotech sector. The chart allows us to compare its volatility with the industry's overall performance, distinguishing its reaction to overall biotech sentiment from sharp movements triggered by Natera-specific news about new tests.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Natera is a leader in genetic testing, particularly in reproductive health. Its growth is driven by the introduction of new tests and meeting medical needs. The chart below shows how Natera's stock price is unaffected by general market fluctuations, driven by its unique news and developments.
Market capitalization of the company, segment and market as a whole
NTRA - Market capitalization of the company Natera Inc.
Natera's market capitalization is a financial roadmap for the future of genetic testing. Its chart reflects not so much current revenue as investor confidence in its platform for reproductive health, oncology, and transplantation. Its volatility reflects scientific breakthroughs and the expanding use of its tests in medicine.
NTRA - Share of the company's market capitalization Natera Inc. within the market segment - Reproduction
Natera is a leader in genetic testing, specializing in reproductive health and oncology. Its market capitalization reflects investors' faith in its technology and growth potential in the personalized medicine market. The chart below shows how Natera is expanding into the early diagnostics market.
Market capitalization of the market segment - Reproduction
Natera is a leader in genetic testing, particularly in reproductive health. The chart below shows the overall market capitalization of the entire biotech sector. Its performance reflects investor confidence in the future of personalized medicine, where Natera holds a key position.
Market capitalization of all companies included in a broad market index - GURU.Markets
Natera is a pioneer in genetic testing, particularly in reproductive medicine. Its market capitalization chart tells the story of how profound scientific knowledge about DNA is turning into a multi-billion-dollar business. It illustrates the growing role of personalized medicine in global healthcare.
Book value capitalization of the company, segment and market as a whole
NTRA - Book value capitalization of the company Natera Inc.
Natera, a genetic testing company, derives its book value from its high-tech laboratories and equipment. The chart below shows how the company is investing in its scientific and technical foundation. Growth within this framework reflects the company's expanded capacity to conduct millions of tests.
NTRA - Share of the company's book capitalization Natera Inc. within the market segment - Reproduction
Natera is a company specializing in genetic testing. Its core asset is the cutting-edge laboratories where it conducts its analyses. The asset share chart shows how the company invests in the unique and expensive physical infrastructure that forms the foundation of its diagnostics business.
Market segment balance sheet capitalization - Reproduction
Against the backdrop of the capital-intensive pharmaceutical industry with its gigantic manufacturing plants, Natera has chosen the diagnostics industry. Its business requires a unique yet focused resource base—advanced laboratories. The graph illustrates the scale of the industry in which Natera occupies its high-tech, less capital-intensive niche.
Book value of all companies included in the broad market index - GURU.Markets
Natera is a leader in genetic testing. The company's assets include cutting-edge laboratories that analyze DNA to identify risks early in life. The chart below illustrates the financial scale of this company, which peers into the "code of life" to protect health.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Natera Inc.
Natera, Inc. is a genetic testing company. The huge premium placed on its laboratory assets reflects its leadership in noninvasive prenatal testing and its potential to expand its technologies to early cancer detection.
Market to book capitalization ratio in a market segment - Reproduction
Natera, Inc. specializes in genetic testing, such as prenatal diagnostics. Its value is determined by the accuracy of its tests, its intellectual property, and the volume of its data. This chart shows how its market valuation, based on growth potential, is many times greater than its book value.
Market to book capitalization ratio for the market as a whole
Natera is a company specializing in genetic testing, particularly in reproductive health. Its main assets are not its laboratories, but rather its unique DNA analysis technologies, patents, and vast amounts of data. This chart shows how investors highly value its scientific potential and leadership in the rapidly growing personalized medicine market.
Debts of the company, segment and market as a whole
NTRA - Company debts Natera Inc.
For Natera, a genetic testing company, debt is a source of funding for large-scale research and commercialization of new tests. The company is active in the fields of reproductive health and oncology, where product development and market launch require significant investment, as this chart illustrates.
Market segment debts - Reproduction
Natera specializes in genetic testing, particularly in reproductive health. This is a fast-growing but highly competitive market, requiring ongoing investment in research and clinical trials. The company's debt load reflects its need for capital to fund innovation. This chart illustrates Natera's financial strategy for profitability.
Market debt in general
Natera, Inc. is a company specializing in genetic testing, particularly in reproductive health and oncology. This is a rapidly growing but capital-intensive market, requiring investment in research. The overall debt profile illustrates the climate in which Natera is raising funds to expand its testing portfolio and commercialize its developments.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Natera Inc.
Natera, a genetic testing company, is at the forefront of medical science, requiring significant investment in R&D. This chart shows how it finances its operations. Its high leverage may reflect investors' faith in its technology, but it also points to the high risks inherent in the biotech sector.
Market segment debt to market segment book capitalization - Reproduction
Natera provides genetic testing services, particularly in the area of reproductive health. This chart shows the debt burden in the biotech sector. It helps understand how companies in this knowledge-intensive industry finance the expensive research and commercialization of their tests, and how Natera manages its growth.
Debt to book value of all companies in the market
Natera is a leader in genetic testing. This chart shows the overall debt level across the market. It allows one to compare Natera's financial model, which requires massive investments in R&D, with the more conservative debt policies of established companies in the economy and evaluate its growth strategy.
P/E of the company, segment and market as a whole
P/E - Natera Inc.
This chart for Natera, Inc. illustrates the valuation of a company leading in genetic testing, particularly in reproductive health and oncology. The company is in a phase of rapid growth. The high valuation reflects not current profits but rather investors' high expectations for the future adoption of its tests in medical practice.
P/E of the market segment - Reproduction
Natera is a company specializing in genetic testing and diagnostics, focusing on reproductive health, oncology, and transplantation. Its tests help make important medical decisions. This chart illustrates the average valuation in the biotech and reproductive medicine sector, where investors evaluate the scientific potential and commercial prospects of new tests.
P/E of the market as a whole
Natera specializes in genetic testing, particularly in reproductive health and early cancer detection. The company's growth is driven by scientific breakthroughs and the adoption of its tests in medical practice. This chart shows overall market sentiment. It helps us understand how much Natera's valuation depends on unique scientific advances rather than general economic trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Natera Inc.
Natera provides genetic testing services, specializing in reproductive health (non-invasive prenatal tests) and oncology. This graph reflects market expectations for the future of personalized medicine. The estimate depends on testing volumes, expanded insurance coverage, and the successful launch of new diagnostic products.
%20P%2FE%20Natera%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Natera-Inc.&v=1772637703593 "Chart of the company's future (projected) P/E Natera Inc.")
Future (projected) P/E of the market segment - Reproduction
Natera provides genetic testing services, specializing in reproductive health and oncology. This chart compares the company's future profitability expectations with the industry average. It reflects the market's confidence that its tests, such as Panorama and Signatera, will become the standard and drive explosive revenue growth.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Reproduction&v=1772637703595 "Future (projected) P/E graph of the market segment - Reproduction")
Future (projected) P/E of the market as a whole
Natera specializes in genetic testing, particularly in reproductive health and oncology. The company's growth is driven by scientific breakthroughs and the introduction of its tests into clinical practice. This market outlook affects Natera primarily through capital availability and investor appetite for risky biotech ventures.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772637703604 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Natera Inc.
Natera specializes in genetic testing for reproductive health, oncology, and transplantation. The company makes money by conducting tests, such as non-invasive prenatal tests. Its financial results depend on the volume of tests performed and reimbursement by insurance companies. The graph shows the growth of the genetic diagnostics market.
Profit of companies in the market segment - Reproduction
Natera is a leader in genetic testing, particularly in reproductive medicine. The company's success depends on innovation and widespread acceptance of its tests by doctors and patients. This chart illustrates how breakthroughs in biotechnology and personalized medicine are shaping a new, rapidly growing, and potentially highly profitable niche in healthcare.
Overall market profit
Natera provides genetic testing services, primarily in the area of reproductive health. Demand for its tests is driven by demographic trends and medical needs, not by the state of the economy. This makes Natera's business unaffected by the cycles visible in this chart and focused on innovation in personalized medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Natera Inc.
Natera is a leader in genetic testing, offering tests for reproductive health, oncology, and transplantation. This graph reflects future revenue expectations, which are directly dependent on the volume of tests performed and the level of reimbursement from insurance companies. Success in bringing new tests to market is a key factor in these forecasts.
%20profit%20of%20the%20company%20Natera%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Natera-Inc.&v=1772637703643 "Graph of future (projected) profit of the company Natera Inc.")
Future (predicted) profit of companies in the market segment - Reproduction
Natera specializes in genetic testing, offering tests for reproductive health, oncology, and transplantation. This chart shows the revenue forecast for the reproductive medicine and genetics sector. It reflects expectations for the implementation of new diagnostic technologies and the willingness of insurance companies to cover costs. This is a key factor in Natera's test volume growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Reproduction&v=1772637703664 "Graph of future (predicted) profits of companies in a market segment - Reproduction")
Future (predicted) profit of the market as a whole
Natera provides genetic testing services, particularly in the area of reproductive health. Its growth is driven by technological innovation and the acceptance of its tests in medical practice. Economic cycles, as reflected here, impact it less than other industries, but can impact patient affordability and insurance reimbursement policies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772637703724 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Natera Inc.
Natera is a company specializing in genetic testing for reproductive health (non-invasive prenatal tests) and oncology. The company's revenue is growing rapidly as its tests are introduced into clinical practice. This chart shows how investors value its sales, factoring in the enormous potential of the genetic diagnostics market.
P/S market segment - Reproduction
Natera is a leader in genetic testing, offering tests for reproductive health, oncology, and transplantation. This is a rapidly growing market at the intersection of medicine and data. This chart reflects the average revenue estimate for the sector, helping to understand the significant premium the market places on innovation and growth potential in Natera's valuation.
P/S of the market as a whole
Natera is a leader in cellular DNA diagnostics, offering tests for reproductive health, oncology, and transplantation. The company is at the forefront of genetic medicine, promising strong growth. This chart compares the high revenue estimates of this high-tech medical device company with the more mundane figures of companies in traditional sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Natera Inc.
Natera is a leader in genetic testing, specializing in reproductive health and oncology. Future revenue depends on the volume of tests performed and the expansion of insurance coverage. This chart reflects investor confidence in the growth of the genetic diagnostics market and Natera's technological leadership.
%20P%2FS%20Natera%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Natera-Inc.&v=1772637703863 "The graph of the company's future (projected) P/S Natera Inc.")
Future (projected) P/S of the market segment - Reproduction
Natera is a leader in genetic testing, specializing in reproductive health, oncology, and transplantation. Its growth is driven by the introduction of innovative tests, such as non-invasive prenatal testing (NIPT). This chart reflects the market's high revenue expectations, based on the potential of its liquid biopsy technology.
%20P%2FS%20market%20segment%20graph%20-%20Reproduction&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Reproduction&v=1772637703963 "Future (projected) P/S market segment graph - Reproduction")
Future (projected) P/S of the market as a whole
Natera provides genetic testing services, particularly in the area of reproductive health. The company's growth depends more on innovation and physician acceptance of its tests than on economics. However, the overall optimism reflected in the chart facilitates access to research capital and increases the willingness of insurance companies to cover the costs of advanced diagnostic tests.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772637704019 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Natera Inc.
Natera is a leader in non-invasive genetic testing. The company's revenue is generated by testing pregnant women (prenatal diagnostics), as well as in oncology and transplantation. The graph shows the growing adoption of genetic testing in clinical practice, opening new horizons for personalized medicine.
Sales of companies in the market segment - Reproduction
Natera is a company specializing in genetic testing. Its business spans several areas: non-invasive prenatal testing, testing for hereditary cancers, and cancer recurrence monitoring. Revenue is generated from every test sold. This graph illustrates the rapid growth of the personalized medicine market, where Natera is one of the innovative leaders.
Overall market sales
Natera provides genetic testing services, primarily in the area of reproductive health. Demand for its tests is driven by demographic trends and medical needs, not by the economy. However, overall economic health, as reflected in this chart, influences insurance coverage and patient access to these advanced tests.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Natera Inc.
Natera is a genetic testing company, a leader in non-invasive prenatal testing (NIPT) and blood-based cancer diagnostics. Revenue growth depends on expanded insurance coverage and the introduction of new tests. This chart reflects analyst forecasts for the company's increased testing volumes and new product launches.
%20sales%20of%20the%20company%20Natera%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Natera-Inc.&v=1772637704227 "Schedule of future (projected) sales of the company Natera Inc.")
Future (projected) sales of companies in the market segment - Reproduction
Natera is a leader in genetic testing, specializing in reproductive health, oncology, and transplantation. This chart shows the outlook for the reproductive medicine sector. Investors should evaluate how innovation and expanded use of Natera's tests, such as in early cancer detection, could enable the company to achieve explosive growth that outpaces the market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Reproduction&v=1772637704243 "Schedule of future (projected) sales of companies in the market segment - Reproduction")
Future (projected) sales of the market as a whole
Natera, Inc., a leader in cellular genetic diagnostics, sees this chart as a reflection of demographic trends and the state of the healthcare system. Rising overall economic forecasts ensure income stability and insurance coverage, making advanced genetic tests, such as non-invasive prenatal testing, more accessible to patients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772637704267 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Natera Inc.
Natera is a company specializing in genetic testing, particularly in reproductive health and oncology. Their success depends on the accuracy of their tests and their acceptance by the medical community. This chart reflects the company's biotech journey: from major investments in research to efforts to monetize their unique technologies and achieve profitability.
Market segment marginality - Reproduction
Natera is a company specializing in genetic testing for reproductive health, oncology, and transplantation. This chart reflects its path to operational efficiency in the fast-growing biotech industry. Improvements in this metric reflect increased testing volumes, such as the Panorama prenatal screening, and cost optimization.
Market marginality as a whole
Natera provides genetic testing services, particularly in the area of reproductive health. The company operates in a rapidly growing market driven by scientific breakthroughs. Its financial performance depends more on the introduction of new tests and insurance coverage than on the overall economic situation, as reflected in this chart.
Employees in the company, segment and market as a whole
Number of employees in the company Natera Inc.
Natera is at the forefront of genetic testing, offering services in reproductive health and oncology. This graph illustrates the exponential growth in the biotech industry. The dramatic increase in the number of lab technicians, scientists, and commercial staff directly reflects the growth in testing volumes and the launch of new diagnostic products.
Share of the company's employees Natera Inc. within the market segment - Reproduction
Natera is a leader in cell-free DNA testing, offering tests for reproductive health, oncology, and transplantation. This chart shows the percentage of leading scientists and geneticists in this cutting-edge field that the company attracts. It's a testament to its scientific leadership and the scale of its efforts to advance personalized medicine.
Number of employees in the market segment - Reproduction
Natera, Inc. is a leader in genetic testing, specializing in reproductive health, oncology, and transplantation. The data in the graph shows the rapid growth of employment in the molecular diagnostics sector. The increase in the number of scientists and laboratory technicians reflects breakthroughs in genetics and the growing use of these tests in clinical practice, where Natera is a pioneer.
Number of employees in the market as a whole
Natera provides genetic testing services, particularly in the area of reproductive health. Their business depends on demographic trends and access to healthcare services. This overall employment chart reflects the financial stability of potential clients. Families with confidence in the future and good health insurance are more likely to utilize advanced diagnostic tests.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Natera Inc. (NTRA)
Natera is a leader in genetic testing, particularly in reproductive health. This chart illustrates the high market valuation of its technology. Its very high market capitalization per employee suggests that the company's value lies in its scientific research, patents, and data, not in the number of lab technicians. It is a business built on intellectual property.
%20of%20the%20company%20Natera%20Inc.%20(NTRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Natera-Inc.-NTRA&v=1772637704438 "Chart of market capitalization per employee (in thousands of dollars) of the company Natera Inc. (NTRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Reproduction
Natera (NTRA) is a leader in genetic testing, particularly in prenatal diagnostics (NIPT) and cancer monitoring. It's a research-intensive, laboratory-based business. This chart shows the market value per employee, reflecting the market's confidence in its technology platform and growth.
%20by%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Reproduction&v=1772637704474 "Market capitalization per employee (in thousands of dollars) by market segment - Reproduction")
Market capitalization per employee (in thousands of dollars) for the overall market
Natera specializes in genetic testing, particularly in reproductive health. The company's value lies in its scientific developments and unique data. This chart demonstrates the high market value per employee, reflecting the enormous potential of its diagnostic tests and its leadership in the rapidly growing field of molecular diagnostics.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772637704502 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Natera Inc. (NTRA)
Natera is a company specializing in genetic testing, particularly in reproductive health (non-invasive prenatal testing). It is a high-tech medical laboratory. This chart shows how effectively the company scales its testing. It reflects how much profit (or loss) each lab and R&D employee generates and is an indicator of their path to profitability.
%20Chart%20Natera%20Inc.%20(NTRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Natera-Inc.-NTRA&v=1772637704503 "Company Profit Per Employee (in thousands of dollars) Chart Natera Inc. (NTRA)")
Profit per employee (in thousands of dollars) in the market segment - Reproduction
Natera is a leader in "liquid biopsy" (non-invasive DNA tests, such as for pregnancy or oncology). This chart shows the benchmark for "Reproduction" (Medtech/Diagnostics). In this sector (high-tech R&D), average profit per employee (scientist) is the future target. Currently, the benchmark reflects the R&D burn through testing.
%20in%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Reproduction&v=1772637704585 "Chart of profit per employee (in thousands of dollars) in the market segment - Reproduction")
Profit per employee (in thousands of dollars) for the market as a whole
Natera is a company specializing in genetic testing, particularly in reproductive health. This is a cutting-edge, science-intensive industry where value is created through unique technologies and research. This chart demonstrates how the team of scientists and technicians monetizes their innovations by bringing sought-after diagnostic tests to the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772637704625 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Natera Inc. (NTRA)
Natera specializes in genetic testing, particularly in reproductive health (non-invasive prenatal tests). This chart shows the dynamics of the fast-growing biotech sector. The growth in revenue per employee reflects the increase in testing volumes, automation of lab processes, and the expansion of the assay portfolio.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Natera-Inc.-NTRA&v=1772637704675 "Sales chart per company employee Natera Inc. (NTRA)")
Sales per employee in the market segment - Reproduction
Natera is a genetic testing company, a leader in non-invasive prenatal screening (NIPT) and cancer recurrence testing. It operates in the R&D and laboratory sectors. This chart shows the sector's average revenue per employee. It helps assess the productivity of their labs and R&D teams.
Sales per employee for the market as a whole
Natera is a company specializing in genetic testing. They are leaders in non-invasive prenatal testing (NIPT) and early cancer detection tests. They are a research-intensive business. This metric reflects how their laboratories and team of scientists generate revenue by analyzing DNA and providing critical medical information.
Short shares by company, segment and market as a whole
Shares shorted by company Natera Inc. (NTRA)
Natera is a genetic testing company, a leader in non-invasive prenatal testing (NIPT) and transplant rejection testing. This chart reflects bearish sentiment. Shorts could be driven by intense competition, regulatory pressure, or litigation over the accuracy of their tests, which poses risks to their reputation and future revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Natera-Inc.-NTRA&v=1772637704752 "Short Shares Chart for the Company Natera Inc. (NTRA)")
Shares shorted by market segment - Reproduction
Natera (NTRA) is a leader in genetic testing, specializing in reproductive health (non-invasive prenatal tests) and cancer monitoring. This chart shows bets against the biotech sector. The rising bets against the industry reflect investor skepticism about the profitability of expensive tests and concerns that insurance companies will refuse to reimburse them.
Shares shorted by the overall market
Natera is at the forefront of genetic testing, specializing in reproductive health. This business requires trust and long-term investment in science. This indicator, reflecting the overall level of fear in the market, is extremely important. When investors are massively "betting against" the market, capital for innovative but risky sectors like Natera becomes more expensive and more fearful.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Natera Inc. (NTRA)
Natera is a pioneer in non-invasive prenatal testing (NIPT). Their business is high-tech diagnostics. This oscillator measures reactions to binary events. Positive news about insurance coverage for their tests (for example, for oncology) can trigger explosive growth and euphoria, pushing the indicator above 70.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Natera-Inc.-NTRA&v=1772637704893 "RSI 14 indicator chart for the company's stock Natera Inc. (NTRA)")
RSI 14 Market Segment - Reproduction
Natera is a company specializing in genetic testing and diagnostics. Their tests are used in reproductive health (non-invasive prenatal testing) and oncology (cancer recurrence monitoring). This chart measures the average momentum in the reproductive medicine and diagnostics segment. It helps distinguish NTRA's movement from the overall industry trend, indicating whether the entire sector is overheated.
RSI 14 for the overall market
Natera (NTRA) is a pioneer in molecular diagnostics. They specialize in non-invasive genetic testing, particularly in reproductive health. They are in the growth-oriented biotech sector. This chart measures overall market euphoria. At times like these, growth stocks like NTRA are often overbought on expectations, and during periods of panic, they can fall sharply.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NTRA (Natera Inc.)
Natera is a pioneer in genetic testing. The company is a leader in non-invasive prenatal testing (NIPT) and is rapidly growing in oncology thanks to its liquid biopsy tests (Signatera). This chart shows how analysts estimate the rate of adoption of these tests by physicians and, more importantly, the expansion of their coverage by insurance companies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NTRA-Natera-Inc.&v=1772637704980 "A chart showing analyst consensus forecasts for the expected stock price. NTRA (Natera Inc.)")
The difference between the consensus estimate and the actual stock price NTRA (Natera Inc.)
Natera is a leader in genetic testing. They specialize in noninvasive prenatal testing (NIPT), as well as early cancer detection and transplant rejection monitoring. This chart shows analyst confidence in their technology platform and the commercialization of new tests. It reflects the gap between the consensus forecast and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NTRA-Natera-Inc.&v=1772637705003 "A chart showing the difference between the consensus forecast and the actual stock price. NTRA (Natera Inc.)")
Analyst consensus forecast for stock prices by market segment - Reproduction
Natera is a leader in genetic testing. The company specializes in noninvasive prenatal testing (NIPT) and cancer recurrence testing (oncology). This chart shows the general expectations of analysts in the biotech and diagnostics sector. It reflects whether experts believe in a genetic testing boom.
Analysts' consensus forecast for the overall market share price
Natera is a leader in molecular diagnostics, specializing in genetic testing for reproductive health and oncology. This is the advanced medicine market. This chart shows the aggregated sentiment of economic analysts. For Natera, a biotech company, it's interesting to see how general market expectations influence R&D funding and the introduction of new, expensive tests. (337)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Natera Inc.
Natera is a technology company specializing in genetic testing. Their flagship products are noninvasive prenatal tests (NIPT) for pregnant women and tests for cancer recurrence monitoring. This chart reflects the exponential growth of the genetic diagnostics market. It measures the volume of tests performed and their success in obtaining reimbursement from insurance companies.
AKIMA Market Segment Index - Reproduction
Natera is a leader in genetic testing; the company dominates noninvasive prenatal testing (NIPT) and is rapidly growing in liquid biopsy (blood-based cancer monitoring). This composite metric evaluates companies. The chart shows the sector average. This benchmark: how does Natera's breakthrough technology (and its consumables model) differentiate it from the average competitor?
The AKIM Index for the overall market
Natera is a leader in genetic testing. The company is best known for its noninvasive prenatal testing (NIPT) and is also rapidly growing in oncology (cancer monitoring). This chart, which reflects the market average, provides context. It helps assess how this growth story in the protective healthcare sector compares to the overall macroeconomic trends impacting the markets.
